Analysts Set Expectations for Teleflex FY2029 Earnings

Teleflex Incorporated (NYSE:TFX) – Equities research analysts at Wolfe Research cut their FY2029 earnings per share estimates for shares of Teleflex in a research report issued to clients and investors on Monday, May 11th. Wolfe Research analyst M. Polark now anticipates that the medical technology company will post earnings of $14.19 per share for the year, down from their previous forecast of $15.36. The consensus estimate for Teleflex’s current full-year earnings is $6.69 per share. Wolfe Research also issued estimates for Teleflex’s FY2030 earnings at $15.60 EPS.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.18. The company had revenue of $548.30 million during the quarter, compared to the consensus estimate of $536.91 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.Teleflex’s revenue was up 32.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS.

Other research analysts also recently issued research reports about the stock. Wells Fargo & Company lifted their price target on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Bank of America upgraded shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price target for the company in a research note on Monday, April 13th. Mizuho set a $140.00 price target on shares of Teleflex in a research note on Friday, May 8th. Truist Financial reiterated a “hold” rating and issued a $143.00 price target (up from $135.00) on shares of Teleflex in a research note on Monday. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research note on Friday, March 27th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Teleflex currently has a consensus rating of “Hold” and an average target price of $144.00.

Teleflex Stock Up 0.7%

Shares of Teleflex stock opened at $129.91 on Thursday. Teleflex has a 52-week low of $100.18 and a 52-week high of $139.67. The company has a 50 day moving average of $120.36 and a 200 day moving average of $116.69. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $5.75 billion, a P/E ratio of -5.70, a P/E/G ratio of 0.96 and a beta of 0.82.

Institutional Investors Weigh In On Teleflex

Several institutional investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise boosted its holdings in shares of Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after acquiring an additional 113 shares during the period. Hantz Financial Services Inc. boosted its holdings in shares of Teleflex by 248.8% in the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after acquiring an additional 199 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Teleflex in the third quarter valued at approximately $35,000. V Square Quantitative Management LLC acquired a new stake in shares of Teleflex in the fourth quarter valued at approximately $37,000. Finally, Quent Capital LLC acquired a new stake in shares of Teleflex in the third quarter valued at approximately $38,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were paid a dividend of $0.34 per share. The ex-dividend date was Friday, March 6th. This represents a $1.36 annualized dividend and a yield of 1.0%. Teleflex’s payout ratio is presently -5.96%.

Teleflex News Roundup

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat first-quarter earnings and revenue estimates, which supports the company’s near-term fundamentals despite a weaker margin profile. TFX Stock Down Post Q1 Earnings & Revenue Beat, Margins Crash
• Positive Sentiment: Needham & Company reaffirmed a Buy rating and a $147 price target, signaling continued confidence in Teleflex’s longer-term earnings power.
• Neutral Sentiment: Several analysts published updated forward EPS estimates for 2026-2028, reflecting ongoing model refreshes rather than a new company announcement; those longer-term forecasts generally still point to earnings growth ahead.
• Negative Sentiment: Wolfe Research trimmed estimates across multiple periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2027, Q1 2028, and FY2028, which can weigh on sentiment because it suggests softer expectations for Teleflex’s future profit trajectory.
• Negative Sentiment: The post-earnings reaction appears tied to a sharp decline in margins and operating profit, with operating profit reportedly down 52.1%, raising concerns that the earnings beat may not be sustainable if profitability keeps deteriorating. TFX Stock Down Post Q1 Earnings & Revenue Beat, Margins Crash

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.